Novi Lek U Veterinarskoj Kliničkoj Praksi – Oklacitinib Maleat

Abstract

Krata sadr ajUvođenjem novog leka oklacitinib maleata u veterinarsku kliničku praksu napravljen je značajan pomak u lečenju alergijskog i kliničkih slučajeva atopijskog dermatitisa (posebno pratećeg svraba) kod pasa.U lečenju ovih bolesti do sada su se najčešće koristili glukokortikoidi, ciklosporin i antihistaminici. Pokazalo se da ciklosporin ima sličnu aktivnost kao i glukokortikoidi, dok je aktivnost antihistaminika slabija. Novi lek oklacitinib maleat ima antiinflamatorni i antipruritični efekt sličan onom koji izazivaju glukokortikoidi i ciklosporin, ali mu (za razliku od njih) efekt brže nastupa, što mu daje veliku prednost.Oklacitinib je imunomodulator i ima specifičan mehanizam delovanja. Deluje tako što inhibira aktivnost enzima janus kinaza (pre svega JAK1 i JAK3), od kojih zavisi funkcija proinflamatornih i pruritogenih citokina.Oklacitinib je prilično bezbedan lek, ukoliko se koristi u kraćem vremenskom periodu i u preporučenim dozama.Klju ne re i:1 Fakultet veterinarske medicine, Univerzitet u Beogradu, Srbija 2 Agencija za lekove i medicinska sredstva, Beograd, Srbija. В т ринарс и урна Р пу и Српс Veterinar Journal of Repu lic of Srps a (Ба а Лу а-Banja Lu a) Во /Vol VII r/NoVitomir Ćupić i sar.: Novi lek u veterinarskoj kliničkoj praksi oklacitinib maleat A stractThe introduction of a new drug oclacitinib maleate in veterinary clinical practice, has been made a big step forward in the treatment of allergic and clinical cases of atopic dermatitis (especially a accompanying pruritus) in dogs.So far glucocorticoids, cyclosporine, and antihistamines were most commonly used in the treatment of the above mentioned diseases. It has been shown that cyclosporine has a similar activity, as glucocorticosteroids, while the activity of antihistamines is weaker. New drug oclacitinib maleate has anti-inflammatory and antipruritic effect similar to that caused by glucocorticoids and cyclosporine, but (unlike them) it achieves more rapidly effect, which gives him a huge advantage.Oclacitinib is an immunomodulator and has a specific mechanism of action. It inhibits the activity of the Janus kinase enzymes (primarily JAK1 and JAK3), from which the function of pro-inflammatory and pruritic cytokines depends.Oclacitinib is a uite safe drug, if used in a shorter period of time, at the recommended doses.